Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jacob Magee Sands, M.D.

Concepts (104)

Concepts are derived automatically from a person's publications.
The timeline below shows the dates (blue tick marks) of publications associated with Jacob Sands's top concepts. The average publication date for each concept is shown as a red circle, illustrating changes in the primary topics that Jacob Sands has written about over time.
Carcinoma, Squamous Cell, 2 publications between 2014 and 2019, average publication date April 2017. Costs and Cost Analysis, 1 publications between 2017 and 2017, average publication date May 2017. High-Throughput Nucleotide Sequencing, 1 publications between 2019 and 2019, average publication date December 2019. Carcinoma, Small Cell, 1 publications between 2020 and 2020, average publication date February 2020. Small Cell Lung Carcinoma, 4 publications between 2018 and 2021, average publication date June 2020. Mutation, 4 publications between 2017 and 2023, average publication date June 2020. Carbolines, 2 publications between 2020 and 2020, average publication date July 2020. Nervous System Diseases, 1 publications between 2020 and 2020, average publication date July 2020. Carcinoma, Non-Small-Cell Lung, 8 publications between 2017 and 2023, average publication date January 2021. Lung Neoplasms, 19 publications between 2017 and 2023, average publication date March 2021. Clinical Trials, Phase III as Topic, 1 publications between 2021 and 2021, average publication date April 2021. Early Detection of Cancer, 5 publications between 2020 and 2022, average publication date November 2021.

To see the data from this visualization as text, click here.
Sands's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (104)
Explore
_
Co-Authors (30)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.